R Fleischmann

1.2k total citations
29 papers, 674 citations indexed

About

R Fleischmann is a scholar working on Rheumatology, Genetics and Immunology. According to data from OpenAlex, R Fleischmann has authored 29 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Rheumatology, 6 papers in Genetics and 6 papers in Immunology. Recurrent topics in R Fleischmann's work include Rheumatoid Arthritis Research and Therapies (18 papers), Systemic Lupus Erythematosus Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). R Fleischmann is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (18 papers), Systemic Lupus Erythematosus Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). R Fleischmann collaborates with scholars based in United States, Canada and Germany. R Fleischmann's co-authors include M H Weisman, Daniel E. Fürst, Fabrizio De Benedetti, Joachim Sieper, A. Gibofsky, Joachim R. Kalden, Nora G. Singer, Thomas E. Dorner, Philip J. Mease and Edward Keystone and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

R Fleischmann

26 papers receiving 642 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R Fleischmann United States	8	375	213	187	90	82	29	674
Ceara AE Walsh Ireland	10	394 1.1×	198 0.9×	158 0.8×	82 0.9×	112 1.4×	11	717
Emma Vernon United States	5	503 1.3×	176 0.8×	256 1.4×	63 0.7×	58 0.7×	9	738
Chiara Bazzani Italy	17	559 1.5×	240 1.1×	186 1.0×	60 0.7×	137 1.7×	38	840
Yonsu Son Japan	16	412 1.1×	264 1.2×	162 0.9×	80 0.9×	47 0.6×	49	712
Anna Laura Fedele Italy	17	479 1.3×	238 1.1×	179 1.0×	172 1.9×	52 0.6×	48	864
Alba Erra Spain	15	421 1.1×	160 0.8×	111 0.6×	107 1.2×	40 0.5×	25	759
Д. Е. Каратеев Russia	11	436 1.2×	188 0.9×	147 0.8×	56 0.6×	36 0.4×	174	667
Francesca Li Gobbi Italy	13	312 0.8×	231 1.1×	73 0.4×	59 0.7×	75 0.9×	59	644
Naonobu Sugiyama Japan	14	480 1.3×	359 1.7×	195 1.0×	61 0.7×	81 1.0×	34	871
M. C. Genovese United States	10	634 1.7×	228 1.1×	320 1.7×	53 0.6×	33 0.4×	38	842

Countries citing papers authored by R Fleischmann

Since Specialization

Citations

This map shows the geographic impact of R Fleischmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Fleischmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Fleischmann more than expected).

Fields of papers citing papers by R Fleischmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Fleischmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Fleischmann. The network helps show where R Fleischmann may publish in the future.

Co-authorship network of co-authors of R Fleischmann

This figure shows the co-authorship network connecting the top 25 collaborators of R Fleischmann. A scholar is included among the top collaborators of R Fleischmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Fleischmann. R Fleischmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fleischmann, R, et al.. (2022). POS0540 CLINICAL OUTCOMES ASSOCIATED WITH GLUCOCORTICOID DISCONTINUATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB OR ADALIMUMAB. Annals of the Rheumatic Diseases. 81. 533–533. 1 indexed citations

Taylor, Peter C., R Fleischmann, Elizabeth L. Perkins, et al.. (2017). Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo. Oxford University Research Archive (ORA) (University of Oxford). 69. 1 indexed citations

Fleischmann, R, Edward Keystone, E. C. Hsia, et al.. (2014). THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Annals of the Rheumatic Diseases. 73. 241–242.

Mease, Philip, R Fleischmann, J. Wollenhaupt, et al.. (2013). EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY. Lara D. Veeken. 52(10). 162–163. 4 indexed citations

Gladman, Dafna D., et al.. (2013). Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis with Certolizumab Pegol: 48-Week Patient-Reported Outcome Results of the Rapid-PsA Study. Value in Health. 16(7). A569–A569. 2 indexed citations

Fleischmann, R, et al.. (2012). Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis. Data Archiving and Networked Services (DANS). 1 indexed citations

Heijde, D. van der, Yoshiya Tanaka, R Fleischmann, et al.. (2012). Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study. Arthritis & Rheumatism. 64(10). 4 indexed citations

Emery, Paul, D. van der Heijde, Mikkel Østergaard, et al.. (2011). Magnetic resonance imaging assessments of patients with RA and their association with clinical and radiographic outcomes. Annals of the Rheumatic Diseases. 70. 1 indexed citations

Weinblatt, M., R Fleischmann, Ronald van Vollenhoven, et al.. (2011). Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study. Data Archiving and Networked Services (DANS). 63(10). 2 indexed citations

10.

Fürst, Daniel E., Edward Keystone, Jürgen Braun, et al.. (2011). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Annals of the Rheumatic Diseases. 70. i2–i36. 317 indexed citations

11.

Strand, Vibeke, O. Purcaru, Ronald van Vollenhoven, Ernest Choy, & R Fleischmann. (2010). PMS62 CERTOLIZUMAB PEGOL MONOTHERAPY PROVIDES SUSTAINED IMPROVEMENTS IN HOUSEHOLD PRODUCTIVITY AND DAILY ACTIVITIES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS OVER 2 YEARS. Value in Health. 13(7). A314–A314. 1 indexed citations

12.

Fleischmann, R, Patrick Durez, P. Emery, et al.. (2008). Golimumab, a new human Anti-TNF-alpha monoclonal antibody, administered subcutaneously everv 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE study. DIAL (Catholic University of Leuven). 58(9). 4 indexed citations

13.

Fleischmann, R, et al.. (2006). Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 65(8). 1006–1012. 228 indexed citations

14.

Fleischmann, R, et al.. (2005). Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Queensland's institutional digital repository (The University of Queensland). 52(9). 7 indexed citations

15.

Vollenhoven, Ronald van, Joy Schechtman, R Fleischmann, et al.. (2005). Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study. Queensland's institutional digital repository (The University of Queensland). 52(9). 12 indexed citations

16.

Ruderman, Eric, et al.. (2000). A PHASE III TRIAL OF ETANERCEPT vs METHOTREXATE (MTX) IN EARLY RHEUMATOID ARTHRITIS (ENBREL ERA TRIAL). 40(2). 229. 32 indexed citations

17.

Clair, E. William St., S. B. Cohen, R Fleischmann, et al.. (2000). Treatment of rheumatoid arthritis with a DR4/1 peptide.. PubMed. 27(8). 1855–63. 11 indexed citations

18.

Fleischmann, R, et al.. (1998). Abdominal ultrasonography: does its routine use affect prognosis?. Gastroenterology. 114. A19–A19. 1 indexed citations

19.

Fleischmann, R. (1991). The long-term U.S. study--a report on outcome and tolerance.. PubMed. 11(3). 50–3. 1 indexed citations

20.

Lazarus, Hillard M., S. B. Cohen, Daniel O. Clegg, et al.. (1991). Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion. 31(2). 122–128. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact